AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S; Brown SP; Belmontes B; Moody G; Keegan KS; Chui D; Whittington DA; Huang X; Poppe L; Cheng AC

doi:10.1158/2159-8290.cd-18-0387

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Identifier:nobleid.org/w1/20260526/80FEB5D2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/80FEB5D2.svg?ark=w1%2F20260526%2F80FEB5D2)](https://nobleid.org/work/w1/20260526/80FEB5D2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Identifier:nobleid.org/w1/20260526/80FEB5D2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/80FEB5D2.svg?ark=w1%2F20260526%2F80FEB5D2)](https://nobleid.org/work/w1/20260526/80FEB5D2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work